Compare GRRRW & YDESW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRRRW | YDESW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United Kingdom | United States |
| Employees | 143 | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | GRRRW | YDESW |
|---|---|---|
| Price | $0.38 | $0.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 336.7K | N/A |
| Earning Date | 04-04-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.28 | N/A |
| Revenue | ★ $78,940,347.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.04 | ★ N/A |
| Revenue Growth | ★ 424.97 | N/A |
| 52 Week Low | $1.06 | N/A |
| 52 Week High | $1.54 | N/A |
| Indicator | GRRRW | YDESW |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 45.38 |
| Support Level | $0.27 | $0.65 |
| Resistance Level | $0.38 | $1.00 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 43.75 | 69.42 |
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.